A phase II randomized, multicentric clinical trail comparing recombinant human endostatin plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locally advanced low-risk nasopharyngeal carcinoma.

Min Kang,Shaomin Lin,Haisheng Zhu,Sihui Liao,Haixin Huang,Bin Yu,Hongqian Wang,Meilian Liu,Jinxian Zhu,Guang Huang,Yu-Tao Qin,Zhu-Xin Wei,Qinghua Du,Kai Hu,Tingting Zhang,Pingting Zhou,Xueyin Liao,Rensheng Wang

A phase II randomized, multicentric clinical trail comparing recombinant human endostatin plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locally advanced low-risk nasopharyngeal carcinoma.

2017

Min Kang
Shaomin Lin
Haisheng Zhu
Sihui Liao
Haixin Huang
Bin Yu
Hongqian Wang
Meilian Liu
Jinxian Zhu
Guang Huang
Yu-Tao Qin
Zhu-Xin Wei
Qinghua Du
Kai Hu
Tingting Zhang
Pingting Zhou
Xueyin Liao
Rensheng Wang

6063Background: A prospective, randomized, and multicentric phase II study was performed to evaluate the short-term efficacy and safety of Endostar plus intensity-modulated radiotherapy (IMRT) vers...

Keywords:

Nasopharyngeal carcinoma
Oncology
Recombinant Human Endostatin
Radiation therapy
Chemoradiotherapy
Pathology
Medicine
Internal medicine
Phases of clinical research
intensity modulated radiotherapy
locally advanced
concurrent chemoradiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations